XTL Biopharmaceuticals Ltd. Market Cap 2011-2026 | XTLB

As of February 22, 2026 XTL Biopharmaceuticals Ltd. has a market cap of $ 442 M

Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.^[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap XTL Biopharmaceuticals Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	-	1.27 B	16.6 M	6.89 M	11.8 M	8.42 M	8.22 M	17.4 M	23.1 M	41.3 M	65.3 M	37.7 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.27 B	6.89 M	137 M

References

Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer	Market Cap	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	315 M	-	2.43 %	$ 254 M	Germany
ARCA biopharma ABIO	484 M	-	1052.0 %	$ 415 M	USA
Autolus Therapeutics plc AUTL	424 M	$ 1.68	2.44 %	$ 429 M	Britain
Acer Therapeutics ACER	12.1 M	-	2.71 %	$ 14 M	USA
Acasti Pharma ACST	40.7 M	-	4.01 %	$ 150 M	Canada
Adverum Biotechnologies ADVM	76.4 M	-	-	$ 86.2 M	USA
Kamada Ltd. KMDA	271 M	$ 8.81	1.73 %	$ 260 M	Israel
I-Mab IMAB	127 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	724 M	-	-	$ 1.01 B	USA
Alexion Pharmaceuticals, Inc. ALXN	33.6 B	-	-	$ 40.3 B	USA
Biophytis SA BPTS	549 M	-	-13.47 %	$ 169 M	France
Adagene ADAG	87.8 M	$ 3.26	0.62 %	$ 183 M	China
Alterity Therapeutics Limited ATHE	895 M	$ 3.28	-2.62 %	$ 7.89 B	Australia
Evogene Ltd. EVGN	66.3 M	$ 0.81	-9.28 %	$ 27.9 M	Israel
EyeGate Pharmaceuticals, Inc. EYEG	28.9 M	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	79 M	-	-18.52 %	$ 27.3 M	Britain
Akero Therapeutics AKRO	3.25 B	-	-	$ 3.67 B	USA
Akouos AKUS	172 M	-	0.23 %	$ 488 M	USA
Nymox Pharmaceutical Corporation NYMX	143 M	-	-19.68 %	$ 18.4 M	Canada
Albireo Pharma ALBO	538 M	-	-0.23 %	$ 916 M	USA
Aptorum Group Limited APM	4.09 M	$ 0.79	-1.29 %	$ 4.31 M	China
Alpine Immune Sciences ALPN	269 M	-	-	$ 2.17 B	USA
AlloVir ALVR	49 M	-	4.14 %	$ 49.1 M	USA
Allena Pharmaceuticals ALNA	71.4 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	664 K	-	-11.43 %	$ 502 K	USA
Acorda Therapeutics ACOR	16.7 M	-	-24.86 %	$ 820 K	USA
Applied Molecular Transport AMTI	22.1 M	-	-	$ 10.1 M	USA
Aptose Biosciences APTO	2.32 M	-	-45.71 %	$ 1.2 M	Canada
Aravive ARAV	60.4 M	-	-13.39 %	$ 1.45 M	USA
Институт стволовых клеток человека ISKJ	2.83 B	-	-	-	Russia
Ascendis Pharma A/S ASND	7.37 B	$ 224.42	-2.52 %	$ 5 B	Danmark
Applied Genetic Technologies Corporation AGTC	32.8 M	-	-	$ 26.5 M	USA
Arena Pharmaceuticals ARNA	5.65 B	-	-6.81 %	$ 3.04 B	USA
Athersys ATHX	364 M	-	3.77 %	$ 22.4 M	USA
AVROBIO AVRO	56.3 M	-	1083.1 %	$ 745 M	USA
Anavex Life Sciences Corp. AVXL	291 M	$ 4.13	0.12 %	$ 352 M	USA
Aeterna Zentaris AEZS	41.4 M	-	5.93 %	$ 314 M	Canada
AgeX Therapeutics AGE	14.1 K	-	-10.17 %	$ 12.2 K	USA
Aytu BioScience AYTU	15.8 M	$ 2.36	2.27 %	$ 14.8 M	USA
Aptinyx APTX	9.48 M	-	-39.0 %	$ 4.57 M	USA
AstraZeneca PLC AZN	81.2 B	-	-	$ 96.9 B	Britain
Aridis Pharmaceuticals ARDS	4.13 M	-	17.91 %	$ 11.1 M	USA
Brickell Biotech BBI	11.4 M	-	-5.38 %	$ 6.06 M	USA
Codexis CDXS	291 M	$ 1.17	-0.85 %	$ 85.9 M	USA
Athira Pharma ATHA	16.2 M	-	-	$ 269 M	USA
BioNTech SE BNTX	62.9 B	$ 110.12	-0.28 %	$ 27.2 B	Germany
Amneal Pharmaceuticals AMRX	1.83 B	$ 14.49	-0.75 %	$ 4.48 B	USA
AIkido Pharma AIKI	19.6 M	-	1.93 %	$ 17.4 M	USA
CureVac N.V. CVAC	3.53 B	-	-	$ 867 M	Germany